PEAK6 LLC purchased a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 199,995 shares of the company's stock, valued at approximately $586,000. PEAK6 LLC owned approximately 0.07% of AbCellera Biologics as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Guardian Partners Inc. acquired a new position in shares of AbCellera Biologics in the 4th quarter worth approximately $5,413,000. Norges Bank bought a new position in AbCellera Biologics during the fourth quarter worth $3,764,000. JPMorgan Chase & Co. boosted its holdings in AbCellera Biologics by 6.4% in the third quarter. JPMorgan Chase & Co. now owns 355,747 shares of the company's stock worth $925,000 after purchasing an additional 21,483 shares during the period. State Street Corp increased its stake in AbCellera Biologics by 1.5% during the third quarter. State Street Corp now owns 323,229 shares of the company's stock valued at $840,000 after purchasing an additional 4,679 shares during the last quarter. Finally, DnB Asset Management AS raised its holdings in shares of AbCellera Biologics by 424.7% during the fourth quarter. DnB Asset Management AS now owns 305,579 shares of the company's stock worth $895,000 after purchasing an additional 247,342 shares during the period. 61.42% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
ABCL has been the subject of a number of recent research reports. Stifel Nicolaus lowered their price objective on shares of AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, February 28th. Benchmark reaffirmed a "hold" rating on shares of AbCellera Biologics in a report on Monday, March 3rd. Finally, KeyCorp raised their price target on AbCellera Biologics from $4.00 to $5.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th.
Read Our Latest Analysis on ABCL
AbCellera Biologics Price Performance
Shares of ABCL stock traded down $0.04 during trading hours on Friday, reaching $2.57. The stock had a trading volume of 2,561,744 shares, compared to its average volume of 2,658,764. The firm has a market capitalization of $764.34 million, a PE ratio of -4.20 and a beta of 0.50. The firm has a 50-day simple moving average of $2.46 and a 200-day simple moving average of $2.77. AbCellera Biologics Inc. has a twelve month low of $1.89 and a twelve month high of $4.34.
About AbCellera Biologics
(
Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Further Reading
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
